3 unknown, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Unknown 3, Not yet recruiting 2, Recruiting 2, Active not recruiting 1 |
Follow telitacicept: new trials by email Literature Review of telitacicept trials Research Report on telitacicept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Telitacicept for the Treatment of Refractory RA Telitacicept - Rheumatoid Arthritis (RA) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 30 | 2025-06-10 | 2025-06-06 |
| Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis Telitacicept - Myasthenia Gravis, Autoimmune Diseases | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 30 | 2024-12-01 | 2024-12-09 |
| Immune Cell Subsets in SLE Patients Treated with Telitacicept Telitacicept 160mg - Systemic Lupus Erythematosus (SLE) | Phase 4 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2024-10-11 | 2024-11-07 |
| The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis Telitacicept - Systemic Sclerosis | Phase 4 | Unknown | Peking University Third Hospital | 20 | 2024-06-08 | 2024-08-09 |
| Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) Telitacicept, Placebo of Telitacicept - ANCA Associated Vasculitis | Phase 4 | Recruiting | Chinese SLE Treatment And Research Group | 40 | 2023-06-29 | 2023-07-27 |
| Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) Azathioprine, Telitacicept - ANCA-associated Vasculitis, Maintenance Therapy | Phase 4 | Recruiting | Chinese SLE Treatment And Research Group | 40 | 2023-03-09 | 2023-07-28 |
| Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients Telitacicept, Hydroxychloroquine, Prednisone - Systemic Lupus Erythematosus | Phase 4 | Unknown | Fen Li | 30 | 2022-12-31 | 2024-01-17 |
| Efficacy and Safety of Telitacicept in Early SLE Telitacicept, Standard of Care - Lupus Erythematosus, Systemic | Phase 4 | Unknown | Peking Union Medical College Hospital | 180 | 2022-09-01 | 2023-06-12 |
Lupus Erythematosus, Systemic (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Myasthenia Gravis (1) · Scleroderma, Systemic (1)
Chinese SLE Treatment And Research Group (3) · Fen Li (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Peking Union Medical College Hospital (1) · Peking University Third Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (7)
Fen Li, doctor (1) · JIng Li, M.D. (1) · Jing Li, MD (1) · Xiaomei Leng (1) · Xinping Tian, MD (1)